Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Future Oncol. 2013 Mar;9(3):355-68. doi: 10.2217/fon.12.189.
Antibody-drug conjugates (ADCs) are a broad class of molecules comprising of a potent cytotoxic agent conjugated with a monoclonal antibody using a chemically stable linker. By selecting a monoclonal antibody directed against a tumor-specific or tumor-associated antigen, ADCs allow the targeted delivery of highly potent cytotoxic agents that result in unacceptable toxicity when administered as free agents. ADCs are currently being developed for the treatment of a wide variety of tumors. In this review, the current clinical and preclinical status of ADCs for the treatment of B-cell non-Hodgkin's lymphoma and B-cell leukemia will be discussed. ADCs have the potential to alter treatment paradigms for these diseases by providing both increased efficacy and improved safety and tolerability over current chemotherapy-based regimens.
抗体药物偶联物（ADCs）是一类广泛的分子，由通过化学稳定的连接子与单克隆抗体偶联的有效细胞毒素剂组成。通过选择针对肿瘤特异性或肿瘤相关抗原的单克隆抗体，ADC 允许靶向递送至当作为游离剂给药时会导致不可接受的毒性的高活性细胞毒素剂。目前正在开发 ADC 用于治疗各种肿瘤。在这篇综述中，将讨论用于治疗 B 细胞非霍奇金淋巴瘤和 B 细胞白血病的 ADC 的临床和临床前现状。ADC 有可能通过提供比当前基于化疗的方案更高的疗效和更好的安全性和耐受性来改变这些疾病的治疗模式。
